Insulin resistance is central to the development of non-alcoholic fatty liver disease (NAFLD), and gestational diabetes mellitus (GDM) is an early marker of insulin resistance. We hypothesized that a history of GDM would identify women at higher risk of NAFLD in middle age.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease in the United States aff ecting up to 20-30% of the western world ( 1 ) . NAFLD encompasses a spectrum of disease ranging from isolated hepatic steatosis to steatosis with infl ammation and hepatocyte injury [non-alcoholic steatohepatitis (NASH)]. NAFLD is an increasingly common cause of cirrhosis and hepatocellular carcinoma and is on trajectory to become the most frequent indication for liver transplantation in the United States ( 2, 3 ) . In light of the increasing prevalence and disease burden of NAFLD it is important to identify persons with NAFLD prior to the development of advanced liver disease.
NAFLD is recognized as the hepatic manifestation of the metabolic syndrome. Th e normal physiologic stress of pregnancy, which causes relative hypertriglyceridemia and increased insulin resistance, may help identify women at an early age who are at risk for the development of NAFLD ( 4 ) . Gestational diabetes mellitus (GDM), defi ned as glucose intolerance fi rst recognized during pregnancy, represents a failure to adapt to the metabolic demands of pregnancy and has been shown to confer an increased risk of subsequent type 2 diabetes mellitus (DM), and the metabolic syndrome, as well as signify a marker for early atherosclerosis independent of pre-pregnancy metabolic risk factors (5) (6) (7) (8) . A single cross-sectional, European study has shown that history of GDM is Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease associated with a signifi cantly higher prevalence of NAFLD compared to healthy volunteers in unadjusted analyses ( 9 ) . However, this study was limited by its small sample size, inability to adjust for pre-pregnancy metabolic risk factors and exclusion of women who subsequently developed DM.
Th erefore, it remains unclear whether GDM is associated with NAFLD independent of other metabolic risk factors or progression to DM. We sought to evaluate the impact of previous GDM on the prevalence of NAFLD in middle age while controlling for known metabolic risk factors in a biracial cohort, which prospectively measured metabolic risk factors at regular intervals during 25 years. We hypothesized that a history of GDM would be directly associated with NAFLD despite adjustment for metabolic risk factors and would identify young women who would benefi t from interventions to prevent future NAFLD.
METHODS

Study population
Th e CARDIA study is a multicenter community-based longitudinal cohort study of cardiovascular disease in young black and white adults 18-30 years of age recruited across 4 US cities (Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA) in 1985-1986. Subjects were not selected based on risk factors for metabolic disease and were recruited by random-digit dialing from total communities, census tract information, or from their health-care plan. Th e study design has been published previously ( 10 ) . In 1985-1986 a total of 5,115 subjects (2787 women, 50% black) were recruited and had scheduled follow-up at years 2, 5, 7, 10, 15, 20, and 25. Th e retention rate was 72% of the surviving cohort at year 25. Institutional review boards at each center approved the study and informed consent was obtained from all of the participants. From the 2,787 women enrolled at baseline we selected women who delivered one or more births, were free of diabetes prior to pregnancy(ies), and underwent computed tomography (CT) quantifi cation of hepatic steatosis 25 years following cohort entry ( n =1,316). We excluded women with other potential causes of hepatic steatosis including alcohol use>2 drinks/day ( n =52), self-report of HIV or chronic hepatitis ( n =26), and medication use associated with steatosis; amiodarone, methotrexate, valproic acid, tamoxifen, steroids, diltiazem, or hormone replacement therapy ( n =123) ( Figure  1 ) . Th e 1,115 women included in this analysis had similar baseline characteristics to those excluded ( Supplementary Table 1 online).
Measurements
Pregnancies and GDM status . Pregnancies and deliveries were assessed by self-report at each exam. Participants reported the number of pregnancies and births, length(s) of gestation, gestational hypertensive disorders, and GDM, as well as how the pregnancy ended (abortion, miscarriage, and live or stillbirths). Births were defi ned as pregnancies of>20 weeks gestation. Total parity was equal to the total number of live births. GDM was defi ned by self-report among those without overt diabetes before pregnancy based on CARDIA laboratory tests. Self-report of GDM has been previously validated in this cohort by review of prenatal glucose tolerance tests for a subsample of 165 women who delivered 200 births and revealed a sensitivity of 100% and specifi city of 92% ( 11 ) .
Assessment of hepatic steatosis . Th e CT protocol used a noncontrast abdominal CT scan performed using GE [GE 750HD (64) of hepatic steatosis was made by measuring liver attenuation (LA) in Hounsfi eld Units (HU). NAFLD was defi ned as a LA value ≤40 HU. LA was the average of nine measurements on three CT slices of the right lobe of the liver. A cut-off of LA value ≤40 HU correlates with moderate-to-severe steatosis (>30%) in unenhanced CT scans in multiple studies (13) (14) (15) . Th e characterization of LA in this cohort used a dedicated workfl ow within the National Institute of Health's Center of Information Technology Medical Image Processing, Analysis, and Visualization application has previously published ( 12 ) . Th e interclass correlation coeffi cient between diff erent readers on a random sample of 156 participants was 0.975 for LA, indicating high reproducibility of CT measured LA in this cohort.
Risk factor measurements . Participant demographics, medical history, and alcohol use were obtained through standardized surveys. Medication use was determined through self-report and participants brought medications to study visits for verifi cation. Participants were asked to fast for ≥8 h prior to venous blood draws at each visit. Procedures for specimen collection and methodologies to assay plasma triglycerides (TG), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and total cholesterol (TC), and serum glucose and insulin were standandized ( 16, 17 ) . Homeostatic model assessment index (HOMA-IR) was calculated using the equation: [fasting glucose (mmol/l) x fasting insulin (mU/l)] /22.5. Certifi ed technicians performed anthropometric measurements including weight, height and waist circumference using standardized protocols. Waist circumference was measured midway between the iliac crest and bottom of the rib cage. Change in BMI was calculated between baseline and Year 25.
Statistical analyses
Baseline and follow-up diff erences in participant characteristics were compared by GDM history using chi-square tests for categorical variables and Mann-Whitney U tests for continuous variables. Logistic regression was used to evaluate the association between previous GDM and NAFLD at year 25. Bivariate models assessed the association between variables chosen a priori for clinical relevance and known association with the outcome of NAFLD. Th ese covariates included age, race, and baseline covariates [BMI, waist circumference, fasting LDL, HDL, triglycerides, and insulin resistance (HOMA-IR)]. Variables were selected for the fi nal multivariate model by backwards elimination with P -value<0.05 used as the threshold for variable inclusion. Change in BMI and incident DM aft er pregnancy were evaluated as mediators of GDM and NAFLD. Eff ect modifi cation by race, baseline BMI, baseline HOMA-IR and incident DM aft er pregnancy on the association between GDM status and NAFLD were evaluated by adding the cross-product terms to the fi nal model, with P values <0.10 used to identify statistically signifi cant inter actions. All P -values were two-sided and statistical signifi cance was defi ned as a P -value<0.05. Analyses were performed using STATA 13.1 (StataCorp, College Station, TX).
RESULTS
Study cohort characteristics
Of the 1,115 women meeting inclusion criteria, 57 and 43% were of black and white race, respectively, with a median (IQR) age of 25 (6) years at baseline. One hundred and twenty-four women (11%) reported a history of GDM and 75 (7%) met the CT definition for NAFLD at year 25. Forty-one (6.4%) black women and 34 (7.2%) white women had NAFLD at year 25. At baseline, compared to women without GDM, those who reported GDM at baseline ( n =27) or developed GDM over the study period ( n =97) had higher BMI [median (IQR), 23 ( Table 2 ), compared to women without GDM, those with a history of GDM had signifi cantly higher HOMA-IR [median (IQR), 2.6 (2.9) vs. 2.0 (2.2)], incidence of DM (49 vs. 7.6%) and greater proportion with parity >2 (32 vs. 24%). Moreover, at the 25-year exam, women with a history of GDM had a more than 2-fold higher prevalence of NAFLD compared to those without GDM (14 vs. 5.8%, P <0.01).
Gestational diabetes and NAFLD at year-25
In unadjusted logistic regression models, the odds of NAFLD at year 25 was 2.56-fold higher (95% CI: 1.44-4.55) in women with GDM than without GDM ( Table 3 ). In multivariable models adjusted for age, parity, baseline BMI, waist circumference, ( Table 3 ) . Adjustment for time from births to year 25 did not aff ect the association between GDM and NAFLD (data not shown). Th e change in BMI per 1 kg/m 2 from baseline to year 25 was evaluated as a mediator ( Table 4 ) , but its addition to the fully adjusted multivariable model did not attenuate the GDM association with odds of NAFLD at year 25, which remained statistically signifi cant (OR: 2.89, 95% CI 1.49-5.59, P =<0.01). Furthermore, the addition of year 25 BMI to the same model similarly had minimal impact on the GDM and NAFLD association (OR: 2.61, 95% CI 1.37-4.96, P <0.01). Th e association of GDM with higher odds of NAFLD at year 25 also remained aft er addition of the change in BMI from the fi rst post-delivery exam to year 25 (data not shown).
Th e association between GDM and NAFLD was no longer statistically signifi cant aft er addition of incident DM to the fully adjusted multivariable model (OR: 1.48, 95% CI 0.73-3.02, P =0.28) ( Table 4 ). Incident DM was strongly associated with NAFLD in the fully adjusted models (OR: 2.77, 95% CI 1.41-5.45 P <0.01), and independently associated with GDM vs. non-GDM (49 vs. 7.6%), suggesting that incident DM may be a mediator on the pathway from GDM to NAFLD. Stratifi ed analysis revealed that the association between GDM and NAFLD was no longer statistically signifi cant among those without incident DM in the fully adjusted model (OR: 1.93, 95% CI (0.72-5.14), P =0.19) ( Table 4 ) even though the prevalence of NAFLD at year 25 was almost twofold higher among women with GDM than without GDM (8.1 vs. 4.5%; Figure 2 ). Among those who had developed incident DM, a history GDM was no longer signifi cantly associated with NAFLD. Additional adjustment for number of years with DM did not impact the results (data not shown). Two-way interaction terms for GDM and race ( P =0.64), baseline BMI ( P =0.14), baseline HOMA-IR ( P =0.20), and incident DM ( P =0.47) were not significantly associated with NAFLD at year 25.
DISCUSSION
Our fi ndings demonstrate that a history of GDM is strongly associated with the presence of NAFLD in middle age aft er adjust- 
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Total cholesterol (per 10 mg/dl increase) steatosis on ultrasound and the study was underpowered to perform adjusted analysis. Two studies from Europe have evaluated other markers of fatty liver among women with GDM. One crosssectional study of 31 European women showed an association between non-diabetic women with a history of GDM and increased hepatocellular lipids on MR spectroscopy, however did not evaluate for secondary causes of hepatic steatosis to make the diagnosis of NAFLD ( 18 ) . Another study of 97 European women (68 GDM) assessed within 3-6 months aft er pregnancy found that previous GDM was associated with a higher score on the fatty liver index (FLI), which is a weighted score based on BMI, waist circumference, triglycerides, and GGT that has been shown to correlate with the presence of NAFLD in a middle-aged European cohort ( 19, 20 ) . Our study compared parous women in a large multicenter cohort with 25 years of follow up and was the fi rst to fi nd a signifi cant association between GDM and NAFLD in midlife aft er adjusting for metabolic risk factors in early adulthood (age 18-30 years) in women without diabetes. We utilized computed tomography to evaluate for hepatic steatosis with a very high interclass correlation coeffi cient. Furthermore, our study population was diverse and is the only one to distinguish GDM history from subsequent development of DM.
Women with GDM in CARDIA have a fourfold greater risk of developing DM relative to women without previous GDM aft er controlling for preconception blood glucose and other risk factors ( 11 ) . A meta-analysis reported a 7-fold greater risk for developing DM relative to women who do not have GDM during pregnancy ( 6 ) . Furthermore, DM is a major risk factor for NAFLD; therefore we evaluated subsequent development of DM as a mediator of the relationship between GDM and NAFLD. We expanded on previous fi ndings in CARDIA that GDM was strongly associated with incident DM ( 11 ) . We found that subsequent onset of DM mediated the GDM and NAFLD association. Previous studies that evaluated the association between GDM and hepatic steatosis restricted to women who had not developed incident DM reported a positive association without covariate adjustment. In our study the relationship between GDM and NAFLD was no longer statistically signifi cant when analyses were restricted to women who had not developed incident DM. However, the prevalence of NAFLD was higher in the GDM group compared to the women without GDM during pregnancy, therefore our study may have been underpowered to assess for an association in this subgroup.
GDM represents a state of increased pancreatic beta cell dysfunction, particularly post-glucose load. Previous studies have shown that women with a history of GDM and postpartum weight retention have increased systemic infl ammation and decreased insulin sensitivity ( 21 ) . In women with GDM plasma TNF-α levels and skeletal muscle TNF-α mRNA remain elevated one-year post-partum ( 22 ) . A dose response eff ect with increasing number of GDM pregnancies would support the hypothesis that GDM is associated with NAFLD independent of DM, however our study was underpowered to assess for this. GDM was associated with NAFLD independent of weight gain over 25 years, age at fi rst pregnancy and age at last pregnancy. Th e temporal relationship between NAFLD and the development of DM could not be explored in this study, howment for other metabolic risk factors in early adulthood and may be mediated through the progression to incident DM aft er GDM pregnancy. Th is is the largest study examining the relationship between GDM and NAFLD and utilized a unique and wellcharacterized cohort of black and white women from multiple regions of the United States with 25 years of anthropometric and metabolic profi ling. As an early risk marker for NAFLD, women with GDM may be viewed as a target group for lifestyle interventions aimed at preventing the sequelae of NAFLD.
Th e only previous study of the association between GDM and NAFLD included 223 women (110 GDM) retrospectively selected from a database that underwent ultrasound assessment of hepatic steatosis less than 10 years aft er pregnancy and had not subsequently developed DM ( 9 ) . Th e cross-sectional analysis did not have data on metabolic risk factors during the participants' childbearing years and all of the women in this study were of European descent. Furthermore, only two women had more than mild Figure 2 . Proportion of participants with NAFLD by DM and GDM status. DM, diabetes mellitus; GDM, gestational diabetes mellitus; NAFLD, nonalcoholic fatty liver disease.
LIVER
Gestational Diabetes and NAFLD ever a previous study with 10-year follow up of women with GDM showed a higher incidence of DM among women with the highest values on fatty liver index (FLI) testing ( 19 ) . In our study the only baseline factors associated with NAFLD on multivariable analysis were HOMA-IR and fasting triglycerides, which coincides with previous data on risk factors for the development of NAFLD ( 23 ) . We explored possible interactions between GDM and baseline BMI, HOMA-IR and race, however none met our threshold for statistical signifi cance. In our study, the association between GDM and NAFLD did not vary signifi cantly by race and our study is the fi rst to establish this association in African-American women. A limitation of our study is the measurement of liver attenuation on non-contrast CT scan at the year 25 follow up visit only, which limits our ability to exclude presence of NAFLD before GDM. However, NALFD at baseline is of low likelihood based on the women's age of enrollment and the low prevalence of NAFLD in young adulthood at time of study enrollment in the mid-1980s ( 24 ) . Furthermore, even if women with GDM had NAFLD at baseline, GDM would remain an early marker able to identify women with NAFLD before they developed overt metabolic disease. Th e lack of liver biochemistry is another limitation, however laboratory testing is neither sensitive nor specifi c for the diagnosis of NAFLD and we excluded secondary causes of hepatic steatosis (e.g., alcohol, medications, and concomitant liver disease) through detailed surveys ( 25 ) . Additional laboratory testing, that could have allowed risk stratifi cation by fi brosis severity among women with GDM and NAFLD through the use of validated scoring systems, was unavailable in this study. Our study identifi ed GDM history by self-report, a method previously validated by chart review of antenatal records of glucose testing and had excellent sensitivity and specifi city ( 11 ) . Our outcome of NAFLD was measured by liver attenuation on non-contrast CT scan. While liver biopsy remains the gold standard for diagnosis of NAFLD, it is invasive and subject to sampling error. We chose our LA cutoff based off of previous studies correlating liver attenuation with histology, which showed excellent specifi city but lower sensitivity for the detection of NAFLD ( 15 ) . Maintaining high specifi city minimizes the impact of measurement bias on our measure of association ( 26 ) , however our liver attenuation cutoff could not detect lesser degrees of pathologic steatosis between 5 and 30%. Magnetic resonance spectroscopy is a more sensitive non-invasive tool for the measurement of hepatic fat content and may have increased the number of women with image-detected steatosis, however it was not available in our cohort. Th e absence of signifi cant racial diff erences in our study may have resulted from our inability to detect lesser degrees of steatosis. Our cohort also did not include Hispanic women or data on genetic polymorphisms including patatin-like phospholipase domain containing protein 3 (PNPLA3), which partially explain racial diff erences in NAFLD. Future studies of the association between GDM and NAFLD should include a multi-ethnic cohort and evaluate patients with lesser degrees of steatosis.
In conclusion, our study shows that GDM history is risk marker for NAFLD in middle-aged women separate from metabolic risk factors in young adulthood. We found that progression to DM aft er pregnancy likely mediates this relationship, however the prevalence of NAFLD remained higher among those with GDM who had not developed incident DM, suggesting a continuum of risk with increasing insulin resistance. In women with a history of GDM both lifestyle and pharmacologic intervention with metformin yielded an approximately 50% reduction in the incidence of DM compared to placebo in the Diabetes Prevention Program ( 27 ) . Currently, there are no guidelines recommending who should be screened for NAFLD, and some societal guidelines specifi cally recommend against screening for NAFLD ( 23 ). However, as therapeutic options for treatment of NAFLD increase and screening modalities improve, this may change. Our study shows that a history of GDM may help to identify young women at risk and allow targeted strategies to prevent morbidity and mortality related to NAFLD.
